SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

GRCE

Grace Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 8h ago SEC0001104659-26-127216
Passive stake amendment
Actionable Insight • Neutral

Monitor whether Nantahala converts its convertible securities and whether it files a 13D (activist) conversion, which would signal a more active stance. The passive certification limits near-term pressure.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nantahala Capital Management filed an amended Schedule 13G disclosing a 7.45% passive stake in Grace Therapeutics as of September 30, 2026, representing 1,654,393 shares (including 1,178,203 shares acquirable within 60 days via convertible securities). The filing updates a prior 13G/A from August 2026; the stake increased from 0% to 7.45% since the prior filing, indicating a new position was established or significantly built up.

Key Financial Metrics

Stake
7.45%
Investor
Nantahala Capital Management, LLC
Investor Type
hedge fund

Key Facts

  • Nantahala Capital Management reported beneficial ownership of 1,654,393 shares of Grace Therapeutics common stock as of September 30, 2026.
  • The stake represents 7.45% of shares outstanding.
  • Includes 1,178,203 shares acquirable within 60 days through exercise of convertible securities.
  • Filer certifies passive intent under Rule 13d-1(b), not seeking control.
  • Prior 13G/A from August 2026 did not disclose any shares (0% ownership), indicating this is a new or significantly increased position.

Financial Impact

Nantahala's stake of 1,654,393 shares is valued at approximately $2.9M based on the $39M market cap and 7.45% ownership.

ownershipdilution

Risk Factors

  • Convertible securities overhang could lead to dilution if exercised.
  • Passive filer could later convert to activist 13D filing.
  • Company has a small market cap ($39M), making large passive stakes more influential.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001104659-26-127216
Document: 0001104659-26-127216-index.html0001104659-26-127216
Document: 0001104659-26-127216.txt0001104659-26-127216

Track record

15 reports on GRCE

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +10.64% at T+5 after the Apr 23, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.75 Now $1.75 0.00% settles Nov 18
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $1.82 Now $1.75 −3.85% settles Nov 17
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $1.81 to $1.81 Now $1.75 −3.31% · 0.00% +0.36% vs SPY
  4. Sep 10, 20269w ago Insider Cluster Bullish 6/10 Entry $2.26 to $2.22 Now $1.75 −22.57% ▼ −1.77% −2.62% vs SPY
  5. Aug 13, 202613w ago 8-K Neutral 5/10 No price data
  6. Aug 13, 202613w ago Press Release Mixed 5/10 Entry $2.07 to $2.16 Now $1.75 −15.46% ▲ +4.35% +4.55% vs SPY
  7. Aug 4, 202614w ago Press Release Neutral 5/10 Entry $2.14 to $2.12 Now $1.75 −18.22% ▼ −0.93% −0.77% vs SPY
  8. Jul 28, 202615w ago 8-K Neutral 5/10 Entry $2.25 to $2.08 Now $1.75 −22.22% ▼ −7.56% −6.02% vs SPY
  9. Jun 18, 202621w ago 8-K Mixed 5/10 Entry $2.38 to $2.26 Now $1.75 −26.47% ▼ −5.04% −4.73% vs SPY
  10. Jun 18, 202621w ago 8-K Bearish 6/10 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens in 7h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026